Midas Koyianis (Mr. Bull) retweeted
$IREN is up to almost $40 in overnight trading
Midas Koyianis (Mr. Bull) retweeted
Same stocks. Different analysts. Not everyone at this round table saw the same chart.
Watch this killer break down 👇
Midas Koyianis (Mr. Bull) retweeted
Wells Fargo sees $NBIS at 7.5GW of ACTIVE capacity by 2030 🔥
What would that mean for Nebius market cap and stock price?
Wells Fargo now projects Nebius will have 7.5GW of fully deployed activated GPUs.
At ~10M per MW revenue that would equate to ~75B ARR by 2030.
Using a conservative valuation multiple of 5X ARR we would be looking at ~375B market cap company by 2030.
(That’s ~12.9X the current market cap of ~29B)
Let’s estimate share count to be ~350M by 2030 accounting for additional dilution.
This would yield a stock price of ~$1,071 a share
$NBIS long game
NFA (Always do your own research)
I would not add the 5 GW+ Nvidia commitment on top of existing plans. I see it more as the total number going into 2030. But maybe Wells Fargo knows more. $NBIS
Midas Koyianis (Mr. Bull) retweeted
1 of the keys to my success at the beginning was I used to sit on calls with @ElliotWaveBull every week reviewing setups.
Having someone there to check you on your ideas and making sure your not breaking any rules is a must.
Midas Koyianis (Mr. Bull) retweeted
How to Own Every Sector of the AI Revolution
AI:
$GOOGL Alphabet
$MSFT Microsoft
Chips:
$NVDA NVIDIA
$AMD Advanced Micro Devices
$TSM Taiwan Semiconductor
$ASML ASML Holding
$MU Micron Technology
Space:
$RKLB Rocket Lab
$ASTS AST SpaceMobile
$PL Planet Labs
$RDW Redwire
Crypto:
$COIN Coinbase
$CIFR Cipher Mining
$IREN Iris Energy
$MARA Marathon Digital
Energy / Grid:
$GEV GE Vernova
$PWR Quanta Services
$ETN Eaton
Drones:
$AVAV AeroVironment
$KTOS Kratos Defense
$RCAT Red Cat Holdings
Nuclear:
$LEU Centrus Energy
$BWXT BWX Technologies
$CCJ Cameco
$OKLO Oklo
Defense:
$PLTR Palantir Technologies
$NOC Northrop Grumman
$LMT Lockheed Martin
Robotics:
$AMZN Amazon
$SERV Serve Robotics
Batteries / Storage:
$FLNC Fluence Energy
$EOSE Eos Energy
Rare Earths:
$MP MP Materials
$CRML Critical Metals Corp
$TMC The Metals Company
Copper:
$FCX Freeport-McMoRan
$SCCO Southern Copper
$TECK Teck Resources
Critical Minerals:
$UUUU Energy Fuels
$TMQ Trilogy Metals
$UAMY United States Antimony
Self-Driving:
$TSLA Tesla
$LAZR Luminar Technologies
Midas Koyianis (Mr. Bull) retweeted
🚨Why Inference & Enterprise Matter More Than People Think $NBIS
Aether + Token Factory aren’t about hype.
They’re about:
- Predictable costs
- Stable usage
- Lower churn
- Enterprise stickiness
AI is moving from experiments → systems.
Nebius is positioning for that phase.
That’s how platforms are built.
Midas Koyianis (Mr. Bull) retweeted
$PLTR will become the most hated company in the world
The way this unfolds will be good for the tech oligarchs and the politicians
But it will be bad for every American
Do you see what’s happening? How can you support this?
The Founding Fathers would be furious
Midas Koyianis (Mr. Bull) retweeted
$ETH Is really starting to look good here 🚨📈
This is really shaping up to be my top pick for 2026..
A very impressive start which just shows how strong investor appetite is in 2026 for this crypto currency.
@fundstrat could be spot on when he shares his views of $ETH being in a super-cycle! 🎯
$ETH CONTINUES TO SHOW GREAT STRENGTH WITH $3,500 BEING THE NEXT TARGET🚨🎯
We saw the break above the 50 day MA last week which is what the $ETH bulls have being trying to achieve since the liquidation crisis back in early October.
There is a clear path to $3,500 which is the 200 day MA, if bulls can flip that to support then we could see an explosive move higher for Ethereum..
Ethereum is one of my biggest convictions in 2026, join my group to follow all my investments and analysis - $4,99 - Coupon Code “2025” - dailymarketmovements.com
Midas Koyianis (Mr. Bull) retweeted
To all $NBIS shareholders, friendly reminder: the thesis remains fully intact. Nothing material has changed.
The company continues to execute exceptionally well. Last quarter, management laid out compelling targets, including 7–9× YoY ARR growth in FY2026.
On top of that, the company secured a $3B agreement with Meta, a deal that, in my view, is very likely to grow further over time.
And let’s not forget: $NBIS STILL HAS A $17B DEAL WITH MICROSOFT.
Even under a very conservative scenario, assuming zero ARR growth in FY2027, the company would generate roughly $8B in FY2027 revenue. At a 20% EBITDA margin, that implies:
• FY2027 P/S of ~3
• FY2027 EV/EBITDA of ~15
Once again, that’s conservative.
Is that really expensive for a company:
• that has grown revenue 355% YoY
• with a 2yr forward revenue CAGR of 430%…
• with a top-notch management
• with many amazing subsidiaries, including Avride, which is among the top AV companies around the world
• with a 28% stake in ClickHouse
Midas Koyianis (Mr. Bull) retweeted
$NFLX
FCF is trending higher
Chart shared in our group today and it’s looking very good here
Midas Koyianis (Mr. Bull) retweeted
#Ethereum continues to build a multi-week base off a major reversal support, and STILL my thesis remains - no reason to sound the alarm as it consolidates at a previous resistance-turned-support zone.
This is where you' want to see a reversal of significance follow #ETH
Midas Koyianis (Mr. Bull) retweeted
$NBIS made a higher high today after a series of higher lows
This shows you that whales are accumulating and the strength of the stock is coming back
Next I am watching for price to retest and flip the $95 prior resistance to support
Some people on X are worried about the $67 gap. To me it doesn't matter even if it gets there (low probability imo) Because if whales are accumulating in the $80s and $90s they will for sure be buying in the $60s and $70s hand over fist
$NBIS
Made another higher low this morning
Buying pressure is strong
I think if bulls can flip $95 from resistance to support, a large breakout is likely happening soon
Midas Koyianis (Mr. Bull) retweeted
It’s so interesting to watch people lose their mind when a stock that ran 500% or 1000% in less than a year pulls back 20%. It’s never linear. Never. 😮💨
Midas Koyianis (Mr. Bull) retweeted
$NVO - I don't think a company with:
- 84% gross margins
- 35.6% net profit margins
- 29% ROIC
- 8% CAGR EPS growth
- 3%+ div yield
Should be trading at a forward PE of just 16.
What do you think?
Midas Koyianis (Mr. Bull) retweeted
Replying to @DaveStockGuy @alexboge
I mainly use Elliott Wave thesis with Fibonacci levels and fair value gaps to create key levels and zones
Currently $ASTS is in Wave 3, which is 90% of the time the biggest Wave. After Wave 3 will be Wave 4 which will be roughly a 30% pullback at the minimum before Wave 5 makes new highs again.
The only difference is when $ASTS is hitting these key levels that could potentially be resistance, I'm not going to blindly assume that the stock is going to immediately pull back for Wave 4. Yes, it is a possibility, but until I see real confirmation, I won't claim it to be Wave 4.
For Wave 3, I have 3 more targets left that this stock could hit. After $102 I have $139, then $182, then $189. I think $ASTS will reject one of these key levels and then we'll see Wave 4. I have charted roughly 100 different stocks and there has only been one stock to defy my strategy and that is $PLTR. $IREN could potentially invalidate this structure as well.
I say this as $ASTS could I guess in theory be the second or third depending on $IREN, but I don't bet on it since it has been a low percentage of times I've seen this happen
Midas Koyianis (Mr. Bull) retweeted
🚨 $NVO Rybelsus approved to reduce heart risk🚨
Yesterday, the FDA approved Novo's oral Semaglutide, Ryblesus,for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
In the SOUL trial, Rybelsus 14 mg lowered major cardiovascular events by 14% versus placebo.
It’s now the first and only oral GLP-1 drug with proven heart benefits. Novo plans a similar approval for oral Wegovy for obesity later in 2025.
This puts Rybelsus in a new position: from a convenient injectable alternative, to a leading therapy. It's likely to strengthen Novo’s dominance in the cardio-metabolic market.
Rybelsus makes up about 7-8% of Novo's total revenue.









































